Stockscreener 앱 받기
47.29
26.97%
7.91
전일 마감가:
$39.38
열려 있는:
$39.71
하루 거래량:
311.58K
Relative Volume:
1.89
시가총액:
$3.60B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-11.50%
1개월 성능:
-8.78%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$37.50
$52.21
1주일 범위
$37.50
$60.58
52주 변동 폭
$9.95
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
MENS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
47.39 | 2.99B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.54 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.99 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.06 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
774.96 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
345.21 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Jyong Biotech Ltd 주식(MENS)의 최신 뉴스
Jyong Biotech (NASDAQ:MENS) Shares Down 8%What's Next? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Shares Gap DownTime to Sell? - MarketBeat
Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards - GlobeNewswire
First Taiwan-Developed Botanical Drug in FDA Phase III: Jyong Biotech Wins Gold for BPH Treatment - Stock Titan
Jyong Biotech (NASDAQ:MENS) Trading Down 6.1%Here's Why - MarketBeat
MENS Stock Price and Chart — NASDAQ:MENS - TradingView
Jyong Biotech (NASDAQ:MENS) Reaches New 52-Week HighStill a Buy? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Shares Gap UpHere's Why - MarketBeat
Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei - GlobeNewswire
Taiwan Biotech Leader Joins Global Business Forum: Jyong CEO to Discuss Cross-Border Innovation - Stock Titan
Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.7%Should You Sell? - MarketBeat
Jyong Biotech completes patient enrollment in Phase II trial of MCS-8 - TipRanks
Jyong Biotech Announces Completion of Patient Enrollment of - GlobeNewswire
Jyong Biotech (NASDAQ:MENS) Sets New 12-Month HighHere's Why - MarketBeat
Enrollment goal met in trial of MCS-8 for prostate cancer prevention - Urology Times
Jyong Biotech completes phase II enrollment of 700+ patients for MCS-8 in prostate cancer prevention trial - MarketScreener
Jyong Biotech (MENS) Wraps Up Phase II Enrollment for Cancer Drug Study - GuruFocus
Jyong Biotech Completes Enrollment in Phase 2 Trial of Prostate Cancer Investigational Drug - MarketScreener
700+ Patient Milestone: Jyong Biotech's Prostate Cancer Prevention Drug Advances in Phase II Trial - Stock Titan
Jyong Biotech (NASDAQ:MENS) Trading Up 9.1%What's Next? - MarketBeat
Evaluating Jyong Biotech (NasdaqGM:MENS): What Recent Price Moves Reveal About Its Current Valuation - Yahoo Finance
Examining Jyong Biotech (NasdaqGM:MENS) Valuation Following Recent Share Price Momentum - simplywall.st
Shared decision-making: Clarifying roles in prostate cancer care - Urology Times
Biopharma IPO activity slows, but 2025 returns are surging - BioWorld MedTech
Jyong Biotech (NASDAQ:MENS) Sets New 52-Week HighStill a Buy? - MarketBeat
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025 - The Motley Fool
Jyong Biotech shares rise 1.06% premarket after being included in a stock market index. - AInvest
Experts discuss the transformative potential of AI for BPH - Urology Times
Jennifer Robles, MD, on future advancements in HoLEP - Urology Times
Jyong Biotech to present clinical data from studies of BOTRESO, MCS-8 - MSN
Jyong Biotech (NASDAQ:MENS) Stock Price Down 6.7%What's Next? - MarketBeat
Jyong Biotech shares rise 1.83% after-hours after participating in the 22nd Urological Association of Asia Congress. - AInvest
Jyong Biotech shares fall 1.93% after-hours following participation in the 22nd Urological Association of Asia Congress. - AInvest
Jyong Biotech Ltd. Participated in the 22nd Urological - GlobeNewswire
Breakthrough: Taiwan's First FDA Phase 3 Botanical Drug BOTRESO Shows Promise in $9.8B BPH Market - Stock Titan
Positive data on BOTRESO and MCS-8 highlight dual advances in prostate health - Urology Times
Jyong Biotech (NASDAQ:MENS) Shares Up 10.5%Here's What Happened - MarketBeat
Biopharma IPO drought continues: chance of rain expected? - BioWorld MedTech
Jennifer Robles, MD, on the impact of regional disparities in HoLEP access - Urology Times
Jyong Biotech Ltd (MENS) 재무 분석
Jyong Biotech Ltd (MENS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
2.06%
자본화:
|
볼륨(24시간):